Han Biomedical

Han Biomedical Debt

The Debt of Han Biomedical (6999.TWO) as of Oct 24, 2026 is 2.18 M TWD. In the previous year, Debt was 5.45 M TWD — a change of -59.96% (lower).

Debt

2.18 MTWD

YoY

-59.96%

Last updated:

In 2024, Han Biomedical's total debt was 2.18 M TWD, a -59.96% change from the 5.45 M TWD total debt recorded in the previous year.

The Han Biomedical Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2022
9.78 M TWD
Jan 1, 2023
5.45 M TWD
Jan 1, 2024
2.18 M TWD
The Han Biomedical Debt history
YEARDebtYoY
2.18 MTWD-59.96%
5.45 MTWD-44.26%
9.78 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Han Biomedical Stock analysis

What does Han Biomedical do? Han Biomedical Inc generates revenue through the design, development, and production of medical materials for tissue reconstruction and repair. Its primary products are BarriGel, a post-surgical anti-adhesion solution that prevents complications by extending degradation time, and Hancare, a collagen scaffolding material made from medical-grade collagen that adheres to wounds and absorbs exudate. The company distributes these products mainly within Taiwan's domestic market, targeting healthcare providers and medical facilities that require advanced tissue repair solutions. The firm focuses on natural biomedical materials, emphasizing product innovation for post-surgical care. BarriGel and Hancare are positioned as specialized medical solutions for wound management and adhesion prevention, catering to hospitals and clinics seeking effective tissue repair technologies. Revenue streams are derived from direct sales of these branded products to domestic healthcare institutions without external distribution channels. Han Biomedical Inc's business model centers on proprietary medical materials developed for specific clinical applications. The company's product portfolio includes BarriGel and Hancare, both designed to address post-surgical challenges with natural materials. Domestic market distribution ensures consistent revenue from local healthcare providers who prioritize advanced tissue repair solutions. Han Biomedical is one of the most popular companies on Eulerpool.

Debt Details

Understanding Han Biomedical's Debt Structure

Han Biomedical's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Han Biomedical's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Han Biomedical’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Han Biomedical’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Han Biomedical stock

Debt of Han Biomedical is 2.18 M TWD in 2024.

Debt of Han Biomedical changed from 5.45 M TWD to 2.18 M TWD, representing a -59.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Han Biomedical since 2006 – with annual values, charts, and detailed analysis.

Debt's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Han Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Han Biomedical

All Key Metrics — Han Biomedical